CNS border posts against rituximab?

Lancet Oncol. 2019 Feb;20(2):169-170. doi: 10.1016/S1470-2045(18)30829-5. Epub 2019 Jan 7.

Authors

Benjamin Kasenda¹, Gerald Illerhaus²

Affiliations

¹ Department of Haematology/Oncology and Palliative Care, Klinikum Stuttgart, Stuttgart Cancer Centre, 70174 Stuttgart, Germany; Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.
² Department of Haematology/Oncology and Palliative Care, Klinikum Stuttgart, Stuttgart Cancer Centre, 70174 Stuttgart, Germany. Electronic address: g.illerhaus@klinikum-stuttgart.de.

PMID: 30630773
DOI: 10.1016/S1470-2045(18)30829-5

No abstract available

Publication types

Comment

MeSH terms

Central Nervous System Neoplasms*
Humans
Lymphoma, Non-Hodgkin*
Rituximab

Substances

Rituximab